291 related articles for article (PubMed ID: 8178840)
1. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group.
Woodruff JD; Pickar JH
Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1213-23. PubMed ID: 8178840
[TBL] [Abstract][Full Text] [Related]
2. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
[TBL] [Abstract][Full Text] [Related]
3. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
4. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
[TBL] [Abstract][Full Text] [Related]
5. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group.
Archer DF; Pickar JH; Bottiglioni F
Obstet Gynecol; 1994 May; 83(5 Pt 1):686-92. PubMed ID: 8164926
[TBL] [Abstract][Full Text] [Related]
6. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium.
Gelfand MM; Ferenczy A
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):398-402. PubMed ID: 2548135
[TBL] [Abstract][Full Text] [Related]
7. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
8. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
9. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.
Greendale GA; Reboussin BA; Hogan P; Barnabei VM; Shumaker S; Johnson S; Barrett-Connor E
Obstet Gynecol; 1998 Dec; 92(6):982-8. PubMed ID: 9840563
[TBL] [Abstract][Full Text] [Related]
10. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
12. Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Menopause Study Group (United States, Italy, Netherlands, Switzerland, Belgium, Germany, and Finland.
Pickar JH; Archer DF
Am J Obstet Gynecol; 1997 Nov; 177(5):1178-83. PubMed ID: 9396916
[TBL] [Abstract][Full Text] [Related]
13. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone.
Portman DJ; Symons JP; Wilborn W; Kempfert NJ
Am J Obstet Gynecol; 2003 Feb; 188(2):334-42. PubMed ID: 12592236
[TBL] [Abstract][Full Text] [Related]
15. Endometrial effects of tibolone.
Archer DF; Hendrix S; Gallagher JC; Rymer J; Skouby S; Ferenczy A; den Hollander W; Stathopoulos V; Helmond FA
J Clin Endocrinol Metab; 2007 Mar; 92(3):911-8. PubMed ID: 17192288
[TBL] [Abstract][Full Text] [Related]
16. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group.
Nand SL; Webster MA; Baber R; O'Connor V
Obstet Gynecol; 1998 May; 91(5 Pt 1):678-84. PubMed ID: 9572210
[TBL] [Abstract][Full Text] [Related]
17. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
18. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.
Kagan R; Abreu P; Andrews E
Postgrad Med; 2018 Nov; 130(8):687-693. PubMed ID: 30280946
[TBL] [Abstract][Full Text] [Related]
19. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.
Figueroa-Casas PR; Ettinger B; Delgado E; Javkin A; Vieder C
Menopause; 2001; 8(6):420-3. PubMed ID: 11723414
[TBL] [Abstract][Full Text] [Related]
20. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement.
Williams DB; Voigt BJ; Fu YS; Schoenfeld MJ; Judd HL
Obstet Gynecol; 1994 Nov; 84(5):787-93. PubMed ID: 7936513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
